Viridian Therapeutics (NASDAQ:VRDN) Price Target Raised to $41.00

Key Points

• Royal Bank of Canada raised its price target on Viridian Therapeutics to $41 from $38 and maintained an “outperform” rating, implying 42.17% upside from the prior close. Analysts’ consensus rating is “Moderate Buy,” with an average target of $41.
• Viridian reported a quarterly loss of $0.81 per share, narrower than the $1.02 analysts expected, while revenue of $25.75 million exceeded the $4.72 million consensus.
• The company remains loss-making: its quarterly loss widened from $0.34 per share a year earlier, and analysts forecast a full-year loss of $4.07 per share.

Viridian Therapeutics (NASDAQ:VRDN - Get Free Report) had its price objective lifted by stock analysts at Royal Bank Of Canada from $38.00 to $41.00 in a research note issued on Thursday, Benzinga reports. The brokerage currently has an "outperform" rating on the stock. Royal Bank Of Canada's price target indicates a potential upside of 42.17% from the stock's previous close.

Several other brokerages also recently commented on VRDN. Truist Financial raised their price objective on Viridian Therapeutics from $39.00 to $42.00 and gave the stock a "buy" rating in a research note on Thursday. HC Wainwright boosted their target price on shares of Viridian Therapeutics from $22.00 to $40.00 and gave the stock a "buy" rating in a report on Thursday. Wells Fargo & Company upped their price target on shares of Viridian Therapeutics from $31.00 to $34.00 and gave the stock an "overweight" rating in a research report on Thursday. Leerink Partners increased their price target on shares of Viridian Therapeutics from $50.00 to $54.00 and gave the company an "outperform" rating in a research note on Thursday. Finally, Weiss Ratings raised shares of Viridian Therapeutics from a "sell (e+)" rating to a "sell (d-)" rating in a research report on Monday, September 14th. Eleven analysts have rated the stock with a Buy rating and one has given a Sell rating to the company's stock. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus target price of $41.00.

Viridian Therapeutics Price Performance

Shares of VRDN stock traded down $0.22 during trading hours on Thursday, hitting $28.84. 2,414,244 shares of the company's stock were exchanged, compared to its average volume of 2,154,895. Viridian Therapeutics has a 52 week low of $13.18 and a 52 week high of $34.29. The stock has a market cap of $3.27 billion, a price-to-earnings ratio of -8.55 and a beta of 1.07. The company has a debt-to-equity ratio of 0.43, a current ratio of 16.95 and a quick ratio of 16.95. The stock's 50-day moving average is $21.80 and its 200-day moving average is $21.85.

Viridian Therapeutics (NASDAQ:VRDN - Get Free Report) last released its quarterly earnings results on Wednesday, November 4th. The company reported ($0.81) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.02) by $0.21. The business had revenue of $25.75 million during the quarter, compared to analysts' expectations of $4.72 million. Viridian Therapeutics had a negative return on equity of 72.97% and a negative net margin of 505.86%. As a group, research analysts forecast that Viridian Therapeutics will post -4.07 EPS for the current year.

Insider Activity

In other news, insider Jennifer Tousignant sold 14,212 shares of Viridian Therapeutics stock in a transaction that occurred on Wednesday, August 19th. The shares were sold at an average price of $24.50, for a total value of $348,194.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 2.40% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Viridian Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Bank of New York Mellon Corp raised its stake in Viridian Therapeutics by 0.3% in the first quarter. Bank of New York Mellon Corp now owns 216,525 shares of the company's stock valued at $4,235,000 after purchasing an additional 659 shares in the last quarter. ProShare Advisors LLC grew its stake in Viridian Therapeutics by 6.6% during the third quarter. ProShare Advisors LLC now owns 12,609 shares of the company's stock worth $260,000 after buying an additional 784 shares in the last quarter. 71 West Capital Partners increased its holdings in Viridian Therapeutics by 4.1% in the 3rd quarter. 71 West Capital Partners now owns 22,282 shares of the company's stock valued at $459,000 after buying an additional 882 shares during the period. Pictet Asset Management Holding SA increased its holdings in Viridian Therapeutics by 13.5% in the 3rd quarter. Pictet Asset Management Holding SA now owns 12,741 shares of the company's stock valued at $262,000 after buying an additional 1,516 shares during the period. Finally, KBC Group NV bought a new position in Viridian Therapeutics in the 1st quarter valued at about $34,000.

More Viridian Therapeutics News

Here are the key news stories impacting Viridian Therapeutics this week:

• Positive Sentiment: Four firms raised their targets and maintained bullish ratings: Truist lifted its target to $42, Wells Fargo to $34, Wedbush to $42, and HC Wainwright to $40. Needham also raised its target to $38. These upgrades point to continued analyst optimism. Truist rating Wells Fargo rating Wedbush rating HC Wainwright rating Needham rating
• Positive Sentiment: Viridian reported a third-quarter loss of $0.81 per share, narrower than analysts’ roughly $1.01–$1.02 estimate, and revenue of $25.75 million versus a $4.72 million consensus. The earnings and revenue beats may support confidence in its progress. Q3 results
• Positive Sentiment: Viridian is targeting broad coverage for its Lumvoa launch in six to nine months and expects to submit an elegrobart biologics license application in the first quarter of 2027. These commercial and regulatory milestones could provide near-term catalysts, though execution remains important. Lumvoa and elegrobart update
• Negative Sentiment: Despite beating estimates, the quarterly loss widened from $0.34 per share a year earlier to $0.81, underscoring that Viridian remains loss-making. A separate commentary also argued the stock may be overvalued even with its new launch, raising valuation concerns after recent optimism. Valuation commentary

About Viridian Therapeutics

Viridian Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing treatments for serious autoimmune diseases. The company's lead research area is thyroid eye disease (TED), a debilitating condition that can cause eye inflammation, swelling, pain and vision-related complications.

Viridian's pipeline is centered on antibodies designed to inhibit the insulin-like growth factor-1 receptor (IGF-1R), a target associated with TED. Its investigational therapies include veligrotug (VRDN-001), an intravenous treatment candidate, and VRDN-003, a subcutaneous formulation being developed to provide a more convenient administration option.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.